The path from drug discovery to market approval is paved with data—millions of data points generated by bioanalytical laboratories around the world. But not all data is created equal. For data to be accepted by regulatory agencies like the FDA and EMA, it must be generated under specific quality standards that ensure reliability, reproducibility, and integrity. GLP-Compliant Laboratory Testing provides this quality framework for nonclinical safety studies, requiring validated methods, documented processes, independent quality assurance, and inspection-ready records. Complementing GLP is Drug Development Testing—the broader suite of bioanalytical services that support discovery, preclinical, clinical, and post-marketing studies. While not all drug development testing must be GLP-compliant, any data submitted to regulators in support of safety or efficacy must meet applicable standards. Understanding when GLP compliance is required, what it entails, and how to maintain it is essential for pharmaceutical companies, CROs, and bioanalytical laboratories. For regulatory affairs professionals, quality assurance managers, and bioanalytical scientists, the comprehensive analysis on GLP-Compliant Laboratory Testing provides essential insights.

H2: Understanding GLP Compliance

GLP-Compliant Laboratory Testing refers to nonclinical laboratory studies conducted according to the Good Laboratory Practice regulations codified in 21 CFR Part 58 (FDA) and OECD Principles of GLP (international). GLP applies to safety studies submitted to regulators in support of research or marketing permits for drugs, biologics, medical devices, and certain chemicals.

The history of GLP dates to the 1970s, when the FDA uncovered widespread fraud and poor practices in toxicology laboratories. The resulting regulations were designed to ensure that nonclinical safety data is credible and reproducible. GLP is not a set of technical standards (how to run a particular test) but rather a quality system (how to organize a laboratory to ensure reliable results).

The core elements of GLP include:

Organization: A clearly defined management structure with a Study Director responsible for the entire study, a Quality Assurance Unit (QAU) independent of study conduct, and qualified personnel with defined responsibilities.

Facilities: Adequate space, environmental controls, and separation of activities to prevent cross-contamination.

Equipment: Calibrated, maintained, and operated according to written SOPs.

Test systems: Characterization of biological systems (animals, cell cultures) including health status, housing, feeding, and environmental conditions.

Test and control articles: Documented receipt, handling, storage, and characterization of the drug being tested and any control substances.

Protocols: Written study plans approved before study initiation, describing objectives, methods, statistical analyses, and criteria for study termination.

Standard operating procedures: Written procedures for all routine laboratory activities, from sample receipt to data archiving.

Performance of the study: Conduct according to the protocol and SOPs, with contemporaneous documentation of all activities.

Reporting: A final report that accurately describes study methods, results, and conclusions, including a QAU statement.

Archives: Retention of all raw data, documentation, specimens, and final reports for a specified period (typically 5+ years after product approval).

Drug Development Testing for nonclinical safety studies must be GLP-compliant if the data will be submitted to regulators. For discovery or early development work not intended for regulatory submission, GLP compliance is not required (though good scientific practice is always expected).

H2: The Role of the Quality Assurance Unit

The Quality Assurance Unit (QAU) is a critical component of GLP-Compliant Laboratory Testing. The QAU is independent of the study conduct personnel and reports to laboratory management. Its responsibilities include:

Protocol review: Reviewing study protocols to ensure they meet GLP requirements before study initiation.

Study-based inspections: Inspecting each phase of each study (e.g., animal dosing, sample collection, bioanalytical analysis) to ensure compliance with the protocol and SOPs.

Facility-based inspections: Periodically inspecting the laboratory facilities, equipment, and processes.

Final report review: Reviewing the final study report to verify that it accurately reflects the raw data and that the study was conducted in compliance with GLP.

Inspection response: Hosting regulatory inspections, providing documentation to inspectors, and ensuring that any observations are addressed with corrective actions.

The QAU must document all inspections and maintain records for regulatory review. If the QAU identifies a significant deviation from GLP, it must be reported to management and documented in the final study report.

Drug Development Testing that is not GLP-compliant may still have internal quality checks, but they do not meet the regulatory requirements for independence and documentation.

H3: GLP vs. Non-GLP Bioanalysis

For Drug Development Testing, the choice between GLP and non-GLP depends on the intended use of the data:

GLP-compliant testing is required for: toxicokinetic analysis of GLP toxicology studies, safety pharmacology studies (CNS, cardiovascular, respiratory), carcinogenicity studies, reproductive toxicity studies, and any other nonclinical study that will be submitted to regulators in support of safety.

Non-GLP testing may be acceptable for: discovery bioanalysis (lead optimization), method development and feasibility studies, exploratory toxicology studies (dose-range finding), mechanistic studies not intended for regulatory submission, and biomarker studies used for internal decision-making only.

Bioanalytical Method Validation for GLP studies must be performed under GLP, with QAU oversight and full documentation. For non-GLP studies, validation may be fit-for-purpose, with less rigorous documentation.

H2: Regulatory Inspections

GLP-Compliant Laboratory Testing facilities are subject to inspections by the FDA's Bioresearch Monitoring (BIMO) program. Inspections are typically unannounced and may cover a specific study (study-based inspection) or the entire facility (facility-based inspection).

During an inspection, FDA investigators will:

Review documentation: Study protocols, final reports, raw data, instrument logs, calibration records, training files, and QAU records.

Interview personnel: Study directors, analysts, QAU staff, and management.

Observe laboratory operations: Sample processing, instrument operation, data recording.

Inspect facilities: Sample storage, instrument placement, archival areas, environmental controls.

Test computerized systems: Audit trails, access controls, backup procedures.

Common inspection findings (FDA Form 483 observations) include:

Incomplete raw data: Missing documentation of sample preparation, instrument parameters, or integration of chromatograms.

Inadequate QAU oversight: Failure to inspect critical phases of the study, insufficient documentation of inspections, QAU staff not independent of study conduct.

SOP deviations: Failure to follow SOPs, lack of SOPs for critical procedures, SOPs that are not current or approved.

Method validation deficiencies: Incomplete validation (missing stability data, inadequate selectivity testing), failure to perform ISR.

Data integrity issues: Missing audit trails, shared user accounts, deletion of raw data.

Serious or repeated violations can lead to warning letters, disqualification of the testing facility (data from the facility will not be accepted by the FDA), or legal action.

H2: Maintaining GLP Compliance

Maintaining GLP-Compliant Laboratory Testing requires ongoing investment in training, systems, and culture. Best practices include:

Regular internal audits: The QAU should conduct routine facility and study-based inspections, not just waiting for regulatory inspections.

Continuous training: All personnel must receive initial GLP training and annual refresher training. Training records must be maintained.

Documentation discipline: All entries are made in ink, errors are single-striked out with initials and date, no erasures or white-out.

Computer system validation: Before implementing any new software, validate it according to a pre-approved plan. Maintain validation documentation.

Mock inspections: Conduct internal mock inspections to identify and correct deficiencies before regulatory inspectors arrive.

Corrective and preventive action (CAPA): When deviations occur, investigate root causes, implement corrective actions, and verify effectiveness.

Drug Development Testing that operates under GLP gains credibility not just with regulators but also with sponsors and partners. Many pharmaceutical companies will only outsource to laboratories that have a demonstrated track record of GLP compliance.

H2: Future Trends

The landscape of GLP-Compliant Laboratory Testing is evolving. The FDA's "Computer Software Assurance" guidance (2022) recognizes that not all software requires the same level of validation—low-risk systems can use less rigorous approaches while high-risk systems require full validation.

Remote inspections, accelerated by the COVID-19 pandemic, are likely to continue as an option, reducing travel costs and scheduling burdens. However, remote inspections require robust electronic document management and video inspection capabilities.

Data integrity expectations continue to increase. The FDA expects that all electronic data be generated, recorded, and retained in accordance with ALCOA+ principles. Laboratories still using paper records must ensure that paper records are complete, legible, and secure.

For Drug Development Testing, the integration of artificial intelligence and machine learning presents new GLP challenges. Can an AI system be considered "validated"? Who is responsible when an AI makes an error? These questions are being addressed by industry working groups and will likely result in updated guidance.

For pharmaceutical companies and CROs seeking to maintain GLP compliance while adopting new technologies, the market research available on Drug Development Testing offers comprehensive guidance on regulatory expectations, best practices, and future trends.